Drug Interactions Between Hydroxyzine and Bilastine
Combining hydroxyzine and bilastine significantly increases the risk of excessive sedation and CNS depression, and this combination should be avoided in clinical practice. While no direct pharmacokinetic interaction studies exist between these two agents, the additive pharmacodynamic effects create substantial safety concerns.
Key Interaction Mechanisms
Additive CNS Depression
Hydroxyzine is a first-generation antihistamine with profound sedative properties that crosses the blood-brain barrier extensively. The FDA label explicitly warns that hydroxyzine's potentiating action must be considered when used with other CNS depressants 1. Although bilastine is classified as non-sedating at therapeutic doses (20 mg), combining it with hydroxyzine would expose patients to:
- Severe drowsiness and performance impairment - Hydroxyzine causes significant sedation that persists beyond its plasma half-life due to prolonged end-organ effects 2
- Impaired driving ability - Drivers taking first-generation antihistamines like hydroxyzine are 1.5 times more likely to be responsible for fatal automobile accidents 2
- Cognitive dysfunction - Performance impairment can exist without subjective awareness of drowsiness 2
Cardiac Safety Concerns
The FDA label warns that hydroxyzine should be used with caution when combined with drugs that prolong the QT interval 1. While bilastine has not been associated with QT prolongation, hydroxyzine carries this risk, particularly when combined with other medications. The combination adds unnecessary cardiac risk without therapeutic benefit.
Evidence Against Combination Therapy
Guidelines explicitly recommend against combining first-generation and second-generation antihistamines 2. The rhinitis practice parameter states that an AM/PM dosing regimen combining a second-generation agent with a first-generation agent "is not a preferred strategy" because:
- First-generation antihistamines dosed at bedtime still cause significant daytime drowsiness and performance impairment
- Antihistamines and their metabolites have prolonged plasma half-lives
- End-organ effects persist longer than plasma levels of the parent compound
The urticaria guidelines note that adding a sedating antihistamine at night to a non-sedating antihistamine by day "probably has little additional clinical effect on urticaria if the H1 receptor is already saturated" 3.
Clinical Recommendations
Choose one agent, not both:
For non-sedating treatment: Use bilastine 20 mg once daily alone. Research demonstrates bilastine produces minimal H1 receptor occupancy (<4%) in the brain, causes no driving impairment, and has no sedative effects even at double the therapeutic dose 4, 5, 6
If sedation is desired (e.g., nighttime pruritus with insomnia): Use hydroxyzine alone at bedtime, but counsel patients extensively about next-day impairment risks
For inadequate response: Up-dose bilastine to 40 mg rather than adding hydroxyzine. Studies show bilastine up-dosing to 40 mg maintains its non-sedating profile while improving efficacy 7, 8
Special Populations at Higher Risk
Elderly patients are particularly vulnerable to this combination due to increased sensitivity to psychomotor impairment, higher fall risk, and greater susceptibility to anticholinergic effects 2. The combination should be strictly avoided in this population.
Patients taking other CNS depressants (alcohol, sedatives, opioids, antidepressants) face compounded impairment risks 2, 1.
Bottom Line
There is no therapeutic rationale for combining these two antihistamines. The combination provides no additional H1-receptor blockade benefit while substantially increasing sedation, cognitive impairment, and safety risks. If bilastine monotherapy is insufficient, increase the bilastine dose to 40 mg or switch to an alternative second-generation antihistamine—do not add hydroxyzine 8.